Psychocutaneous Drug Therapy

Seminars in Cutaneous Medicine and Surgery

Volumn 22, Issue 3, 2003, Pages 222-233

  Lee, Chai Sue ^b   Koo, John ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; AMANTADINE; AMFEBUTAMONE; BENZATROPINE; BENZATROPINE MESILATE; BENZODIAZEPINE DERIVATIVE; BUSPIRONE; CITALOPRAM; CYPROHEPTADINE; DIPHENHYDRAMINE; DOXEPIN; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; FLUVOXAMINE MALEATE; HALOPERIDOL; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; OLANZAPINE; PAROXETINE; PIMOZIDE; PSYCHOTROPIC AGENT; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE; YOHIMBINE;

AGITATION; AKATHISIA; ANOREXIA; ANORGASMIA; ANTICHOLINERGIC EFFECT; ANXIETY DISORDER; BRADYKINESIA; CLINICAL PRACTICE; CONSTIPATION; DELUSIONAL DISORDER; DEPRESSION; DIARRHEA; DISEASE CLASSIFICATION; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG MECHANISM; DRUG THERAPY; DRUG TOLERABILITY; EJACULATION DISORDER; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; GASTROINTESTINAL TOXICITY; HEADACHE; HUMAN; INSOMNIA; LIBIDO DISORDER; MENTAL DISEASE; NAUSEA; NERVOUSNESS; OBSESSIVE COMPULSIVE DISORDER; ORTHOSTATIC HYPOTENSION; PARKINSONISM; PSYCHOCUTANEOUS DISEASE; PSYCHOSIS; REVIEW; RIGIDITY; SEDATION; SEXUAL DYSFUNCTION; SOCIAL PSYCHOLOGY; SUSTAINED RELEASE PREPARATION; SWEATING; TREMOR; URINE RETENTION; VERTIGO; VISUAL IMPAIRMENT; WEIGHT GAIN; WEIGHT REDUCTION; WITHDRAWAL SYNDROME; XEROSTOMIA;

ANXIETY DISORDERS; DEPRESSIVE DISORDER; HUMANS; MENTAL DISORDERS; OBSESSIVE-COMPULSIVE DISORDER; PSYCHOTROPIC DRUGS; SCHIZOPHRENIA, PARANOID; SKIN DISEASES;

EID: 0242610342     PISSN: 10855629     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1085-5629(03)00045-2     Document Type: Review

References (49)

1. Koo J: Psychodermatology: A practical manual for clinicians. Curr Probl Dermatol 7:199-234, 1995
2. Koo J, Pham CT: Psychodermatology: Practical guidelines on pharmacotherapy. Arch Dermatol 128:381-388, 1992
3. Gorman JM, Kent JM: SSRIs and SNRIs: Broad spectrum of efficacy beyond major depression. J Clin Psychiatry 60(suppl 4):33-38, 1999
4. Settle Jr EC: Antidepressant drugs: Disturbing and potentially dangerous adverse effects. J Clin Psychiatry 59(suppl 16):25-30, 1998
5. Gitlin MJ: Psychotropic medications and their effects on sexual function: Diagnosis, biology, and treatment approaches. J Clin Psychiatr 55:406-413, 1994
6. Feiger A, Kiev A, Shrivastava RK, et al: Nafazodone versus sertraline in outpatients with major depression: focus on efficacy, tolerability, and effects on sexual function and satisfaction. J Clin Psychiatry 57(suppl 2):53-62, 1996
7. Modell JG, Katholi CR, Modell JD, et al: Comparative sexual side effects of bupropion, fluoxetine, paroxetine, and sertraline. Clin Pharmacol Ther 61:476-487, 1997
8. Kavoussi RJ, Segraves RT, Hughes AR, et al: Double-blind comparison of bupropion sustained release and sertraline in depressed outpatients. J Clin Psychiatry 58:532-537, 1997
9. Zajecka JM: The effect of nefazodone on comorbid anxiety symptoms associated with depression: Experience in family practice and psychiatric outpatient settings. J Clin Psychiatry 57:10-14, 1996
10. Fawcett J, Marcus RN, Anton SF, et al: Response of anxiety and agitation symptoms during nefazodone treatment of major depression. J Clin Psychiatry 56:37-42, 1995
11. Eison AS, Eison MS, Torrente JR, et al: Nefazodone: Preclinical pharmacology of a new antidepressant. Psychopharmacol Bull 26:311-315, 1990
12. Taylor DP, Smith DW, Hyslop DK, et al: Receptor binding and atypical antidepressant drug discovery, in O'Brien RA (ed): Receptor Binding and Drug Research. New York, NY, Marcel Dekker, 1986, pp 151-165
13. Horst WD, Preskorn SH: Mechanisms of action and clinical characteristics of three atypical antidepressants: Venlafaxine, nefazodone, bupropion. J Affective Disorders 51:237-254, 1998
14. Ware JC, McBrayer R, Rose V: REM sleep enhancement by nefazodone, trazodone, and buspirone. Sleep Res 22:51, 1993
15. Nofzinger EA, Reynolds III CF, Thase ME, et al: REM sleep enhancement by bupropion in depressed men. Am J Psychiatry 152:274-276, 1995
16. Armitage R, Roffwarg HP, Cain J, et al: The effect of nefazodone on ultradian rhythms in EEG frequencies in major depression. Sleep Res 22:32, 1993
17. Sharpley AL, Walsh AE, Cowen PJ: Nefazodone-a novel antidepressant-may increase REM sleep. Biol Psychiatry 31: 1070-1073, 1992
18. Richelson E: Biological basis of depression and therapeutic relevance, J Clin Psychiatry 52(suppl):4-10, 1991
19. Davidson J: Seizures and bupropion: a review. J Clin Psychiatry 50:256-261, 1989
20. Preskorn SH: Antidepressant response and plasma concentrations of bupropion. J Clin Psychiatry 44:137-139, 1983
21. Preskorn SH: Should bupropion dosage be adjusted based upon therapeutic drug monitoring? Psychopharmacol Bull 27:637-643, 1991
22. Preskorn SH, Katz SE: Bupropion plasma levels: Intraindividual and interindividual variability. Ann Clin Psychiatr 1:59-61, 1989
23. Silverstone PH, Ravindran Afor the Venlafaxine XR 360 Canadian Study Group: Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. J Clin Psychiatry 60:22-28, 1999
24. th Congress of the European College of Neuropsychopharmacology Oct 31-Nov 4, 1998 Paris, France [abstract]
25. th Congress of the European College of Neuropsychopharmacology; Oct 31-Nov 4, 1998; Paris, France.
26. th Congress of the European College of Neuropsychopharmacology; Oct 31-Nov 4, 1998; Paris, France.
27. Montgomery SA: Venlafaxine: A new dimension in antidepressant pharmacotherapy. J Clin Psychiatry 54:119-126, 1993
28. Feighner JP: The role of venlafaxine in rational antidepressant therapy. J Clin Psychiatry 55:62-68, 1994
29. Guelfi JD, White C, Hackett D, et al: Effectiveness of venlafaxine in patients hospitalized for major depression and melancholia. J Clin Psychiatry 56:450-458, 1995
30. Rudolph RL, Fabre LF, Feighner J, et al: Randomized, placebo-controlled, dose-response trial of venlafaxine hydrochloride in the treatment of major depression. J Clin Psychiatry 59:116-122, 1998
31. Benkert O, Grunder G, Wetzel H, et al: A randomized, double-blind comparison of a rapidly escalating dose of venlafaxine and imipramine in inpatients with major depression and melancholia. J Psychiatr Res 30:441-452, 1996
32. Clerc GE, Ruimy P, Verdeau-Pailles J: A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. Int. Clin Psychopharmacol 9:139-143, 1994
33. Lecrubier Y, Bourin M, Moon CAL, et al: Efficacy of venlafaxine in depressive illness in general practice. Acta Psychiatr Scand 95:485-493, 1997
34. Shrivastava RK, Cohn C, Crowder J, et al: Long-term safety and clinical acceptability of venlafaxine and imipramine in outpatients with major depression. J Clin Psychopharmacol 14:322-329, 1994
35. Preskorn SH: Antidepressant drug selection: criteria and options. J Clin Psychiatry 55:6-22, 1994
36. Muth EA, Haskins JT, Moyer JA, et al: Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative. Biochem Pharmacol 35:4493-4497, 1986
37. Friedel RO, Raskind MA: Relationship of blood levels of Sinequan to clinical effects in the treatment of depression in aged patients, in Mendels J, (ed): A monograph of recent clinical studies. Lawrenceville, NJ, Excerpta Medica, 1975
38. Leonard HL, Swedo SE, Lenane MC, et al: A 2- to 7-year follow-up study of 54 obsessive-compulsive children and adolescents. Arch Gen Psychiatry 50:429-439, 1993
39. Rasmussen SA, Eisen JL: Treatment strategies for chronic and refractory obsessive-compulsive disorder. J Clin Psychiatry 58(suppl 13):9-13, 1997
40. Swedo SE, Rapoport JL, Leonard H, et al: Obsessive-compulsive disorder in children and adolescents: Clinical phenomenology of 70 consecutive cases. Arch Gen Psychiatry 46:335-341, 1989
41. Leonard HL: New developments in the treatment of obsessive-compulsive disorder. J Clin Psychiatry 58(suppl 14):39-45, 1997
42. Torch E, Bishop E: Delusions of parasitosis: Psychotherapeutic engagement. Am J Psychother 35:101-106, 1981
43. Koo J, Gambla C: Delusions of parasitosis and other forms of monosymptomatic hypochondriacal psychosis. Dermatol Clin 14:429-438, 1996
44. Koo J, Lee CS: Delusions of parasitosis: A dermatologist's guide to diagnosis and treatment. JAAD 2:285-90, 2001
45. Linskov R: Delusions of infestations treated with pimozide. Acta Derm Venereol 65:267-270, 1985
46. Driscoll MS, Rothe MJ, Grant-Kels JM, et al: Delusional parasitosis: A dermatologic, psychiatric and pharmacologic approach. JAAD 29:1023-1033, 1993
47. Schatzberg AF, Cole JO, DeBattista C: Manual of Clinical Psychopharmacology (ed 3). Washington, DC, APA Press, 1997, pp 154-155
48. Stahl SM: Selecting an atypical antipsychotic by combining clinical experience with guidelines from clinical trials. J Clin Psychiatry 60(suppl 10):31-41, 1999
49. Brown CS, Markowitz JS, Moore TR, et al: Atypical antipsychotics: Part II adverse effects, drug interactions and costs. Ann Pharmacother 33:210-217, 1999